miR-1297 mediates PTEN expression and contributes to cell progression in LSCC
- Department of the Seven-year Clinical, Tianjin Medical University, 22 Qixiangtai Road, Heping District, Tianjin 300070, People's Republic of China (China)
- Department of Otolaryngological, Tianjin Medical University General Hospital, 152 Anshan Road, Heping District, Tianjin 300052, People's Republic of China (China)
Highlights: Black-Right-Pointing-Pointer miR-1297 was found to be overexpressed in LSCC and contribute to the cell progression. Black-Right-Pointing-Pointer PTEN was confirmed to be a target gene of miR-1297. Black-Right-Pointing-Pointer Downregulation of PTEN can rescue the proliferation and invasion ability of miR-1297 downregulated Hep-2 cells. Black-Right-Pointing-Pointer Downregulation of miR-1297 inhibits tumor growth in vivo. -- Abstract: MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression after transcription, and are involved in cancer development. Laryngeal squamous cell carcinoma (LSCC) is one of the most common malignant neoplasms with increasing incidence in recent years. In this paper, we report the overexpression of miR-1297 in LSCC and Hep-2 cells. In addition, PTEN was identified to be directly regulated by miR-1297 through western blot and luciferase activity assay. Furthermore, downregulation of miR-1297 in Hep-2 cells was shown to inhibit cancer cell proliferation, migration, and tumor genesis. Our results document a new epigenetic mechanism for PTEN regulation in LSCC, which is crucial for the development of these tumors.
- OSTI ID:
- 22210288
- Journal Information:
- Biochemical and Biophysical Research Communications, Journal Name: Biochemical and Biophysical Research Communications Journal Issue: 2 Vol. 427; ISSN 0006-291X; ISSN BBRCA9
- Country of Publication:
- United States
- Language:
- English
Similar Records
MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA
miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer